Edgar T. Overton, MD

Head Regional Medical Director
ViiV Healthcare

Disclosure(s): ViiV Healthcare: Employment, Stocks/Bonds (Public Company)

Poster(s):

• (P-396) PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy after Switch
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET